All together, these findings suggest that both mitochondrial insufficiency and HIF-1α-mediated glycolytic reprogramming contribute to T cell exhaustion and that pharmacological inhibition of glycolytic reprogramming is a feasible metabolic intervention strategy to maintain the stemness, longevity, and functionality of (CAR) T cells during chronic viral infection and cancer immunotherapy. This evidence concerns the gene HIF1A and cancer.